Key Points
- CEO Daniel Patrick O’Day sold 15,000 Gilead shares for approximately $2.23 million at an average price of $148.64. The sale, conducted under a pre-arranged Rule 10b5-1 plan, reduced his direct holdings by 2.53%.
- Gilead reported quarterly revenue of $7.80 billion, exceeding analyst estimates of $7.40 billion, while adjusted earnings per share also beat expectations. Revenue increased 10.6% year over year.
- The company declared a quarterly dividend of $0.82 per share, or $3.28 annualized, representing a 2.2% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $158.04.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total value of $2,229,600.00. Following the completion of the sale, the chief executive officer directly owned 577,133 shares of the company's stock, valued at approximately $85,785,049.12. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Patrick O'day also recently made the following trade(s):
- On Monday, August 3rd, Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00.
- On Wednesday, July 1st, Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00.
Gilead Sciences Trading Down 0.2%
GILD stock opened at $149.61 on Thursday. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29. The stock has a market cap of $185.51 billion, a price-to-earnings ratio of -56.03 and a beta of 0.33. The company has a fifty day moving average price of $135.66 and a two-hundred day moving average price of $136.45. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company's revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.01 earnings per share. Equities analysts anticipate that Gilead Sciences, Inc. will post -0.47 EPS for the current year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.
Hedge Funds Weigh In On Gilead Sciences
Institutional investors and hedge funds have recently made changes to their positions in the stock. Range Advisory LLC grew its position in Gilead Sciences by 15.5% in the 2nd quarter. Range Advisory LLC now owns 2,668 shares of the biopharmaceutical company's stock valued at $337,000 after purchasing an additional 359 shares during the period. Tucker Asset Management LLC boosted its stake in Gilead Sciences by 6.5% in the second quarter. Tucker Asset Management LLC now owns 3,970 shares of the biopharmaceutical company's stock valued at $502,000 after acquiring an additional 242 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Gilead Sciences by 5.8% during the 2nd quarter. HighTower Advisors LLC now owns 1,534,627 shares of the biopharmaceutical company's stock worth $193,885,000 after acquiring an additional 84,450 shares during the period. Groupe la Francaise lifted its holdings in Gilead Sciences by 30.9% during the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company's stock worth $6,270,000 after purchasing an additional 11,712 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Gilead Sciences in the 2nd quarter worth about $130,420,000. Institutional investors own 83.67% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently commented on GILD. Barclays decreased their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 29th. Royal Bank Of Canada upped their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a "sector perform" rating in a research note on Wednesday, August 5th. Rothschild & Co Redburn reduced their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Finally, Daiwa Securities Group lowered their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $158.04.
Get Our Latest Stock Report on GILD
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Zacks upgraded Gilead to “Strong Buy.” The upgrade reflects improving expectations for the company’s earnings outlook and could encourage additional buying interest. Gilead Upgraded to Strong Buy
- Positive Sentiment: Zacks raised its 2027 EPS forecasts across every quarter and for the full year. Estimates increased to $2.09 for Q1, $2.24 for Q2, $2.43 for Q3, $2.60 for Q4 and $9.36 for full-year 2027, signaling modestly stronger anticipated profitability. Zacks Gilead Upgrade and Forecasts
- Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio. The single-tablet treatment is aimed at underserved patients and could provide a new source of growth, though commercial adoption will determine its financial impact. Bixlenvo HIV Growth Opportunity
- Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The transaction reduced his holdings by 2.53%, but it was executed under a pre-arranged Rule 10b5-1 plan, making it a weaker bearish signal than an unexpected discretionary sale. SEC Insider Trading Filing
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
